Skip to main content
Premium Trial:

Request an Annual Quote

Diagnostics-For-All, Harvard Ink Pact to Bring Protein Dx Chips to Third World

Diagnostics-For-All, a recently formed non-profit company co-founded by a Harvard University professor, is looking to improve the health of developing nations by offering them certain lab-on-a-chip-based diagnostic tests for free or at low-cost.
Last month, Diagnostics-For-All and Harvard announced a collaboration to make the chip technology, which tests body fluids for proteins indicative of diseases such as tuberculosis and AIDS, available to countries that have limited access to complex laboratory diagnostic equipment.
The collaboration is the latest in a series of tech-transfer deals out of Harvard with an eye toward increasing access to medical and life-science technologies to third-world countries.
The technology, which is still a few years away from being ready for mass use, was created by Harvard chemistry professor George Whitesides, who is also a co-founder of the company.
Under an agreement whose details are still being negotiated, DFA, located in Cambridge, Mass., would likely exclusively license the technology from the university without having to pay royalties when it sells or donates it to developing countries.
However, the company would have to pay royalties to the university if the chips are marketed and sold commercially, university officials told ProteoMonitor, a BTW sister publication.
“We are fulfilling our public mission, which is to make sure these technologies reach fruition, are developed to their fullest potential, and are made as widely available to the general public as is possible,” said Larry Schlossman, a spokesman for the university’s Office of Technology Development.
Last year, Harvard signed two other high-profile, so-called “socially responsible” licensing agreements, to increase the access of technologies developed at the university to underserved nations.
Last October Harvard announced a licensing deal with China’s Morningside Group for protein capsular matrix vaccine technology developed by faculty member John Mekalanos (see BTW, 10/29/2007).
The PCMV technology enables pharmaceutical companies to produce vaccines rapidly and inexpensively; and to more easily develop multivalent vaccines to enable protection against multiple pathogens through one vaccination.
Under the terms of that agreement, Morningside formed a new company to develop and commercialize the PCMV technology and ensure that vaccines incorporating the technology are made available at what it called “reasonably affordable prices” in countries eligible to receive support from the Global Alliance for Vaccines and Immunization.
Harvard also agreed to relinquish its share of future royalties on sales made by Morningside’s company and its affiliates in GAVI countries, and reserved the right to directly license qualified governmental bodies and non-governmental organizations to distribute vaccines made with the PCMV technology for humanitarian purposes.
In March, the university granted a royalty-free license to non-profit group Medicines in Need, known as MEND, to distribute in developing nations an inhalable tuberculosis vaccine developed by Harvard professor David Edwards. MEND is also pursuing commercial markets for its products in the developed world to support its charitable mission.
The vaccine was recently shown to be more effective in animal models than an injectable version, and is expected to enter Phase I safety trials next year (see BTW, 3/26/2008).
One for All
The lab-on-a-chip technology DFA licensed last month is a paper-based microfluidic chip about the size of a fingernail and pre-treated with reagents for color-based assays.
According to a statement issued jointly by Harvard and DFA, the paper is patterned with hydrophobic polymers, “forming a series of channels that guide a fluid sample to the pre-treated regions of the chip. The resulting color changes can then be read and translated into a diagnosis using a key tied to the particular test being conducted.”

“We are fulfilling our public mission, which is to make sure these technologies reach fruition, are developed to their fullest potential, and are made as widely available to the general public as is possible.”

Because the chips are made of paper, they cost as little as a penny to use, significantly cheaper than other similar chips on the market or in development, which are made of silicon, plastic, or glass, according to Harvard and DFA.
There are other types of paper-based diagnostics — for example, pregnancy tests — but “those are, I would say, a primitive form of what this technology enables, where one has miniaturized it very substantially. Because of that miniaturization, [it] can incorporate a whole battery of different tests in a single diagnostic chip, if you will,” James Barber, executive director of DFA since June 1, told ProteoMonitor last week.
Because the chip is still being optimized, he could not say how many different diseases a single chip would be able to test for, but said there was a “handful” in laboratory testing.
The technology is also portable and requires no specialized equipment, complex pumps or power sources. Instead, the chips use the paper’s natural capillary action. The result is that they can be used in settings to quickly determine a patient diagnosis in settings where there are no laboratories or only minimal medical infrastructure.
The chips, which are meant to be used once and then thrown away, have been developed initially for use with blood and urine but eventually will be designed for use with saliva and sweat, as well, Barber said.
DFA is initially targeting the chip for infectious diseases such as malaria, tuberculosis, hepatitis, and HIV and other sexually transmitted diseases, as well as the functions of major organs, such as kidney and liver, which can be adversely affected by the ailments and drug therapies for them. A spokesperson for DFA told BTW this week that the company has not yet decided what specific underserved nations it will target with the technology.
“What we have with this technology is the means to help address significant diagnostic disparities between the United States and the developing world,” Whitesides said in a statement.
For example, in the US, a test for drug-related liver complications takes just hours for results to be returned, but in other parts of the world, it could take weeks, he said. “By developing a low-cost and broadly-applicable test system designated to be deployed in regions with no or little access to complex laboratory diagnostic equipment, we hope to make a real impact on public health,” Whitesides said.
The chips, however, are still not ready to be manufactured on a mass scale, and the company is now concentrating on “translating what have been lab prototype procedures into full-scale manufacturing procedures,” Barber said. He added that that step could be a few years away. DFA is also currently looking for a manufacturing partner, though Barber declined to comment on specifics.
Barber said that the chip is not meant as a replacement for other high-end, more expensive diagnostic methods such as cell cytometry and microscopy.
“Certainly as one goes to very high-end, highly instrumented tests, one can do things we can’t do here,” he said. “This will be very fast as compared to very slow, very inexpensive versus more expensive, but some of those other techniques would be more quantitative than these would be initially.”
He also said that it was too early to compare the accuracy of the chip with existing diagnostic tests since results for the chip are coming off laboratory prototype tests and not off manufacturing lines.
“But intrinsically, these will be highly reproducible, sensitive tests,” he said.
The lab-on-a-chip is the first technology in DFA’s developing portfolio, but as the company gets off the ground, others will be added. Barber declined to describe them, but said that they are based on work being done in Whitesides laboratory.
The overarching theme to all the technology that DFA is interested in is that they are simple and inexpensive alternatives to other methods and platforms on the market and don’t require a laboratory setting or highly skilled and trained staff.
Formed just a few months ago, DFA aims to improve the health of developing nations by providing them diagnostic tests to which they currently don’t have access, Barber said.
That mission, he said, “has been driven by an interest in serving the needs of the developing world, which [is] heavily medically underserved today.” These chips “are really to allow medical personnel who right now don’t have any effective way of either diagnosing certain disease states in the field or monitoring the health of patients who are being treated for those diseases in the field. It’s to allow them to have a way of doing those things that from a practical standpoint they just don’t have at all.”
— Ben Butkus contributed to this report.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.